Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Top Cited Papers
Open Access
- 1 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (1), 31-44
- https://doi.org/10.1038/s41375-020-01016-0
Abstract
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.This publication has 77 references indexed in Scilit:
- Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: summary of a systematic reviewInfluenza and Other Respiratory Viruses, 2013
- Risk of Invasive Haemophilus influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine EraClinical and Vaccine Immunology, 2012
- Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor ResponsesClinical Cancer Research, 2012
- Monoclonal gammopathy of undetermined significance and risk of infections: a population-based studyHaematologica, 2011
- Enhanced Immune Response after a Second Dose of an AS03-Adjuvanted H1N1 Influenza A Vaccine in Patients after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodiesJCI Insight, 2011
- Comparative Study of Immune Status to Infectious Agents in Elderly Patients with Multiple Myeloma, Waldenstrom's Macroglobulinemia, and Monoclonal Gammopathy of Undetermined SignificanceClinical and Vaccine Immunology, 2011
- Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostHaematologica, 2010
- Utility of Influenza Vaccination for Oncology PatientsJournal of Clinical Oncology, 2010
- Effects of Ageing and Gender on Naturally Acquired Antibodies to Pneumococcal Capsular Polysaccharides and Virulence-Associated ProteinsClinical and Vaccine Immunology, 2008